Exelixis (EXEL) Expected to Announce Quarterly Earnings on Tuesday

Exelixis (NASDAQ:EXEL - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Tuesday, April 29th. Analysts expect Exelixis to post earnings of $0.41 per share and revenue of $497.89 million for the quarter.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, analysts expect Exelixis to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Exelixis Price Performance

Exelixis stock traded up $0.22 during midday trading on Friday, reaching $37.43. The company's stock had a trading volume of 1,709,889 shares, compared to its average volume of 2,176,661. The stock's 50-day simple moving average is $36.61 and its 200-day simple moving average is $34.52. The stock has a market capitalization of $10.32 billion, a P/E ratio of 21.15, a PEG ratio of 1.13 and a beta of 0.57. Exelixis has a 52-week low of $20.14 and a 52-week high of $40.02.

Analyst Upgrades and Downgrades

EXEL has been the topic of a number of research analyst reports. Stephens reissued an "equal weight" rating and set a $29.00 price objective on shares of Exelixis in a report on Wednesday, February 12th. Wells Fargo & Company restated a "market outperform" rating on shares of Exelixis in a research note on Thursday, April 17th. Piper Sandler upped their target price on Exelixis from $37.00 to $38.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. JMP Securities reissued a "market outperform" rating and set a $41.00 price target on shares of Exelixis in a research report on Thursday, April 17th. Finally, Stifel Nicolaus upped their price objective on shares of Exelixis from $30.00 to $36.00 and gave the company a "hold" rating in a report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Exelixis has an average rating of "Moderate Buy" and an average target price of $37.59.

Insider Buying and Selling at Exelixis

In related news, Director Mary C. Beckerle sold 12,210 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $34.88, for a total transaction of $425,884.80. Following the completion of the sale, the director now directly owns 30,406 shares in the company, valued at approximately $1,060,561.28. The trade was a 28.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Patrick J. Haley sold 52,636 shares of Exelixis stock in a transaction on Monday, February 24th. The stock was sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the sale, the executive vice president now directly owns 303,310 shares in the company, valued at approximately $11,216,403.80. This trade represents a 14.79 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 140,343 shares of company stock valued at $5,177,234 over the last ninety days. Corporate insiders own 2.85% of the company's stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.